Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the ...

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

By Jacob Gronholt-Pedersen and Stine Jacobsen COPENHAGEN (Reuters) -Newly-elected chairman of Wegovy-maker Novo Nordisk, Lars ...

Finally, the stock now looks reasonably valued, especially given significant clinical and commercial catalysts on the horizon ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.